Axitinib - Pfizer

Drug Profile

Axitinib - Pfizer

Alternative Names: AG-013736; AG-13,736; Inlyta

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Grupo Espanol de Tumores Neuroendocrinos; H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme; Netherlands Cancer Institute; Pfizer; SCRI Development Innovations; SFJ Pharmaceuticals; University of Cincinnati; University of Texas M. D. Anderson Cancer Center; University of Wisconsin-Madison
  • Class Antineoplastics; Eye disorder therapies; Imidazoles; Indazoles; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II/III Neuroendocrine tumours
  • Phase II Carcinoid tumour; Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Prostate cancer
  • Phase I Hepatocellular carcinoma
  • No development reported Solid tumours
  • Discontinued Breast cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Pancreatic cancer; Thyroid cancer

Most Recent Events

  • 10 Apr 2018 Interim efficacy and adverse events data from a phase III ATLAS trial in Renal cell carcinoma released by Pfizer
  • 21 Mar 2018 Pfizer plans the Javelin Medley VEGF phase II trial for Non-Small Cell Lung Cancer and Urogenital cancer (Late-stage disease, Second-line therapy or greater) in April 2018 , (NCT03472560)
  • 30 Jan 2018 Pfizer discontinues phase I development in Renal cell carcinoma (Combination therapy with crizotinib) (Pfizer pipeline, March 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top